High-Dose Chemotherapy With Autologous Stem-Cell Support As Adjuvant Therapy in Breast Cancer: Overview of 15 Randomized Trials

PURPOSE: Adjuvant high-dose chemotherapy (HDC) with autologous hematopoietic stem-cell transplantation (AHST) for high-risk primary breast cancer has not been shown to prolong survival. Individual trials have had limited power to show overall benefit or benefits within subsets. METHODS: We assembled...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Clin Oncol
Asıl Yazarlar: Berry, Donald A., Ueno, Naoto T., Johnson, Marcella M., Lei, Xiudong, Caputo, Jean, Rodenhuis, Sjoerd, Peters, William P., Leonard, Robert C., Barlow, William E., Tallman, Martin S., Bergh, Jonas, Nitz, Ulrike A., Gianni, Alessandro M., Basser, Russell L., Zander, Axel R., Coombes, R. Charles, Roché, Henri, Tokuda, Yutaka, de Vries, Elisabeth G.E., Hortobagyi, Gabriel N., Crown, John P., Pedrazzoli, Paolo, Bregni, Marco, Demirer, Taner
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Clinical Oncology 2011
Konular:
ORIGINAL REPORTS
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4322115/
https://ncbi.nlm.nih.gov/pubmed/21768471
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2010.32.5910
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller